Mallinckrodt Specialty Generics dba SpecGx LLC
Following a July 31, 2025 corporate combination and subsequent separation, two independent companies operate from the same legacy: one focused on specialty therapeutics for rare or underserved conditions across multiple clinical areas, and the other focused on development and large-scale manufacture of generics, sterile injectables, and APIs supported by a U.S.-based manufacturing network.
Industries
N/A
Services
Specialty therapeutics development
Development of specialty therapeutics focused on rare, stigmatized, or unaddressed conditions across immunology, urology, hepatology, ophthalmology, orthopedics, and critical care.
Generic, sterile injectable, and API development and manufacturing
End-to-end development and commercial manufacturing of generic medicines, sterile injectables, and active pharmaceutical ingredients supported by a U.S.-advantaged manufacturing network.
Specialty therapeutics development
Development of specialty therapeutics focused on rare, stigmatized, or unaddressed conditions across immunology, urology, hepatology, ophthalmology, orthopedics, and critical care.
Generic, sterile injectable, and API development and manufacturing
End-to-end development and commercial manufacturing of generic medicines, sterile injectables, and active pharmaceutical ingredients supported by a U.S.-advantaged manufacturing network.
Expertise Areas
- Specialty therapeutics development
- Generic pharmaceuticals
- Sterile injectable manufacturing
- API manufacturing
Key Technologies
- Generic drug formulation
- Aseptic/sterile manufacturing and fill-finish
- API synthesis and scale-up
- Commercial pharmaceutical manufacturing network